TG Therapeutics, Inc.
TGTX
$42.54
-$0.60-1.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -14.15% | -94.11% | 1,286.79% | 457.06% | -78.31% |
| Total Depreciation and Amortization | 52.38% | 23.53% | 30.77% | 62.50% | -11.11% |
| Total Amortization of Deferred Charges | -4.86% | 0.29% | -0.29% | -0.57% | -1.12% |
| Total Other Non-Cash Items | -22.23% | 111.67% | -2,337.81% | 8.48% | 26.34% |
| Change in Net Operating Assets | -56.62% | 31.17% | -76.13% | 24.31% | 20.08% |
| Cash from Operations | -191.02% | 184.91% | -411.36% | 125.90% | -11.99% |
| Capital Expenditure | 23.88% | 16.25% | -90.48% | -68.00% | -19.05% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 36.98% | -133.53% | 1,275.77% | 69.40% | -181.66% |
| Cash from Investing | 36.92% | -133.73% | 1,261.40% | 69.14% | -181.92% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -27.88% | -- | -100.00% | 1,957.14% | -96.32% |
| Repurchase of Common Stock | -- | 100.00% | -1,038.07% | -12.28% | 7.38% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 36,840.36% | 101.35% | -1,114.37% | -5.59% | -0.49% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 7,047.07% | 109.23% | -1,735.01% | 93.72% | -199.85% |